• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Obstetrics

Uterine cavity lavage may detect gynecological malignancies

byMonica ParksandDavid Wang
November 28, 2015
in Obstetrics, Surgery
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In a proof-of-concept study of 35 patients with ovarian or endometrial cancer, the use of uterine cavity lavage successfully produced malignant cells for DNA mutation analysis in all cases.

Evidence Rating Level: 3 (Average)       

Study Rundown: Ovarian cancer (OC) and endometrial cancer (EC) account for a significant proportion of deaths related to gynecologic cancers. A significant proportion of these patients present with advanced disease, as there are limited tools for screening and early diagnosis. Previous studies have demonstrated that liquid Papanicolaou tests may collect shed cancer cells within the cervix. Thus, the purpose of this proof-of-concept study was to investigate whether lavage of the uterine cavity can be used to collect and identify gynecological cancer cells.

The trial performed uterine cavity lavage in 35 patients with known diagnosis of OC and EC along with 27 patients with benign gynecological conditions. Specific mutations within these malignant cells were detected using next-generation sequencing and singleplex amplification analysis. At the conclusion of the trial, uterine cavity lavage produced adequate malignant cells for analysis in all patients. Furthermore, more than 80% of the OC and EC patient cohort had specific mutations detected in sequencing analysis. Of note, the specific mutations in the OC and EC cohort were significantly different from that of the benign disease cohort. The results of this trial support further investigations of uterine cavity lavage as a potential diagnostic test for OC and EC. The study was limited by the small sample size and the lack of patients with early disease. Additional large, prospective trials in patients are needed to determine the utility of uterine cavity lavage as a diagnostic and potential screening tool for OC and EC.

Click to read the study in JCO

Relevant Reading: Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers

In-Depth [prospective cohort]: This study included a total of 65 patients with OC (n = 30), EC (n = 5), benign gynecologic lesions (n = 27), and other malignancies (n = 3). Patients were excluded if they had a history of greater than one primary malignancy, previous tubal ligation or germline mutations. All uterine lavage specimens were analyzed using next-generation sequencing (NGS) or singleplex amplification and compared with the corresponding tumor tissue analysis. At the conclusion of the trial, all lavage samples returned sufficient amounts of DNA for testing. Overall, 80% of the OC cohort and 100% of the EC cohort had specific mutations detected on NGS or singleplex amplification.  The majority of patients with OC had TP53 mutations. In the benign gynecological disease cohort, the majority of patients demonstrated specific mutation in the KRAS gene, which was not significantly detected in the OC or EC mutational analysis.

RELATED REPORTS

Intraperitoneal chemotherapy improves advanced ovarian cancer survival [Classics Series]

Rucaparib compared to standard-of-care chemotherapy showed promising clinical and safe response to treat BRCA1 or BRCA2 mutated, relapsed ovarian carcinoma

Trametinib improves progression-free survival among patients with low-grade serous ovarian carcinoma

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: endometrial cancerovarian canceruterine cavity lavage
Previous Post

Lopinavir-ritonavir prophylaxis not superior to lamivudine in preventing HIV in breastfeeding infants [ANRS 12174 trial]

Next Post

Interventional neuroradiology procedures may deliver lens radiation doses exceeding safe thresholds

RelatedReports

The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Hematology/Oncology Classics

Intraperitoneal chemotherapy improves advanced ovarian cancer survival [Classics Series]

June 30, 2022
Quick Take: Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma
Oncology

Rucaparib compared to standard-of-care chemotherapy showed promising clinical and safe response to treat BRCA1 or BRCA2 mutated, relapsed ovarian carcinoma

March 21, 2022
The SOLO1 trial: Olaparib significantly delays progression of advanced ovarian cancer
Chronic Disease

Trametinib improves progression-free survival among patients with low-grade serous ovarian carcinoma

February 15, 2022
Recurrence of endometrial hyperplasia following medical therapy is common
Oncology

Lenvatinib plus pembrolizumab increased survival for advanced endometrial cancer patients when compared to chemotherapy

March 27, 2022
Next Post
Interventional neuroradiology procedures may deliver lens radiation doses exceeding safe thresholds

Interventional neuroradiology procedures may deliver lens radiation doses exceeding safe thresholds

Higher parental monitoring linked to safer sex in teens

Higher parental monitoring linked to safer sex in teens

Adverse pregnancy outcomes associated with thrombophilias [Classics Series]

The CHARM-Added trial: Adding candesartan to ACE inhibitor reduces mortality in heart failure [Classics Series]

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • The RAPTURE trial: Radiofrequency ablation effective and safe in lung cancer [Classics Series]
  • Relugolix combination therapy is efficacious for endometriosis-associated pain
  • Age-based products and longer interdose intervals may reduce the risk of cardiac disease following COVID-19 mRNA vaccination
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.